Novavax COVID-19 booster shot granted EUA for adults

0
18

Shares of Novavax Inc. NVAX, -3.71% rallied 1.9% in morning trading Wednesday, after the biotechnology company said its protein-based COVID-19 vaccine booster was granted emergency use authorization (EUA) for adults. The booster shot is OK’d for people at least 18 years old who have completed primary vaccinations. The company said in trials, any local and systemic reactions from the booster had a median duration of about two days. Of those receiving the booster, 81.1% had pain/tenderness at the sight of the shot, 63.4% felt fatigue/malaise, 63.0% had muscle pain, 52.9% had headaches, 30.3% felt joint pain and 14.7% had nausea/vomiting. The booster now awaits recommendation for use as a first booster from the Centers for Disease Control and Prevention (CDC). The stock has tumbled 67.3% over the past three months, while the S&P 500 SPX, -0.67% has declined 5.6%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous article: Adjustable-rate mortgage applications rise to highest level since March 2008. House buyers take risk on rates falling (eventually).
Next articleNokia shares drop 5% after reporting results

LEAVE A REPLY

Please enter your comment!
Please enter your name here